Atopic Dermatitis

This year’s virtual atopic dermatitis conference takes place on Sunday, December 10, 2023.

Colleen Cotton, MD, discusses the treatment landscape of pediatric atopic dermatitis, highlights from her session at Maui Derm NP+PA in Asheville, NC, and more.

Non-physician posts accumulated more than 3 times the number of views compared to those created by physicians. Among physicians, dermatologists demonstrated higher average view counts compared to non-dermatologists.

As cold weather is approaching for much of the country, it is crucial for dermatologists, pediatricians, and families to work together for proper pediatric atopic dermatitis care.

Experts in dermatology share their insights on how to approach corticosteroid hesitancy in their dermatology patient populations.

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C comment on the practical aspects of utilizing topical corticosteroids, including potency, formulation, administration, and utility.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.

No concerns were cited about the clinical data package, safety, or label of lebrikizumab.

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss pearls and key take-aways from their experience managing atopic dermatitis. Jennifer Holman wraps up discussing anticipated therapeutic developments and unmet needs.

Jennifer Holman, MD, FAAD, reflects on the improvements in therapeutic treatments and outcomes for patients like Audrey Dean, and how her experience and quality of life has also improved with these medical advances.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss how treatment with upadacitinib for atopic dermatitis has improved her quality of life.

Ruth Ann Vleugels, MD, and Christopher Bunick, MD, agreed that the long-term safety data for JAK inhibitors makes them preferable to systemic steroids.

Efficacy of 1% colloidal oatmeal cream was similar to prescription barrier cream in treating mild to moderate atopic dermatitis.

Peter Lio, MD, offers perspectives on topical steroid withdrawal, also known as red skin syndrome or topical steroid addiction.

Audrey Dean discusses her experience of atopic dermatitis therapeutic side effects with her dermatologist, Jennifer Holman, MD, FAAD. Jennifer Holman goes on to highlight key pearls on managing patients with atopic dermatitis.

Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.

Natural and synthetic antimicrobial peptides can penetrate deeper skin layers.

Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

Investigators found a steady reduction of IgE levels in patients regardless of dupilumab dosing interval.

Roflumilast cream .05% for mild to moderate atopic dermatitis in children also met secondary endpoints.

The Small Business Innovation Research grant enables ResVita Bio to develop RVB-101 for treatment of severe atopic dermatitis.